Recruiting
Phase 2

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Sponsor:

IDEAYA Biosciences

Code:

NCT05907954

Conditions

Uveal Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Darovasertib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information